latest news releases from the newsroom
Ceragenin(TM) Compound Demonstrates Potent Activity Against Multidrug Resistant Bacterial Strains of Pseudomonas
DENVER--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology today announced that researchers at the Eugene Appelbaum College of Pharmacy at the Wayne State University, in collaboration with JMI Laboratories and Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments that an investigational drug compound known as CSA-13 shows rapid killing activity and synergistic activity with conventional antibiotics against multidrug resistant Pseudomonas aeuroginosa bacterial strains. P. aeuroginosa is a leading cause of morbidity and mortality in patients with pneuomonia and other respiratory diseases. The research appears ahead of print in the December online publication of the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.
Pride International, Inc.
Pride International, Inc. Provides Update on Fleet Contract Status and Guidance on 2008 Estimated Capital Expenditures
HOUSTON, Dec. 20, 2007 (PRIME NEWSWIRE) -- Pride International, Inc. (NYSE:PDE) today announced that its report of drilling rig status and contract information covering the company's fleet of offshore drilling rigs, its five drilling management projects, along with a summary status of its Eastern Hemisphere-based land fleet, has been updated as of December 19, 2007. The report also provides an estimate of 2008 rig out-of-service time resulting from planned shipyard programs and time required for rig mobilizations. The updated report, titled "Monthly Fleet Update," is available through the company's worldwide web address at www.prideinternational.com and can be accessed at the Investor Relations link.